Just a quick, permanent reminder for everyone following along. The brands we discuss may offer affiliate compensation or discounts on research products and materials. However: Everything we write — research summaries, interpretations, opinions, and any product commentary — is developed completely independently by the ELEVATE research community. No brand, manufacturer, or supplier reviews, approves, edits, or directs any of it. Ever. In fact, the opposite is frequently true. If anyone makes a statement about a product on this page, that statement is solely the view of the independent researcher who posted it. It is never the claim, position, endorsement or representation of any manufacturer, supplier, or brand. The compounds discussed here are research chemicals intended strictly for laboratory and research use only. They are not for human consumption. Any discussion of published studies, mechanisms, results, or product graphics is purely educational and informational. None of it constitutes medical advice, nor is it a recommendation, suggestion, or endorsement of non-research human use. All statements on this page reflect our independent research community’s analysis only. Variables exist in every research setting. Never treat any post, thread, graphic, or comment as the manufacturer’s position or as guidance for personal use. Appreciate y’all. Keep on researching.

BROMANTANE + BEMETHYL | THE ORIGINAL ACTOPROTECTORS Long before Bromantane became popular in the nootropic community, Soviet researchers were investigating something entirely different: compounds capable of maintaining physical performance under extreme physiological stress. Bromantane wasn’t originally developed as a conventional cognitive enhancer. Its roots were in actoprotection, a pharmacological approach aimed at preserving work capacity during fatigue, heat exposure, hypoxia, and other demanding conditions. THE EARLY RESEARCH In 1999, Morozov and colleagues described screening 329 adamantane derivatives, with Bromantane emerging as a leading candidate. Earlier rodent experiments reported several interesting findings: • Increased physical work capacity in swimming and treadmill models, with effects lasting at least 24 hours. • Performance exceeding an amphetamine comparator under the specific experimental conditions. • Faster recovery following repeated bouts of extreme physical exertion. • Reduced exercise-associated mitochondrial damage in cardiac and skeletal muscle tissue. Researchers proposed that Bromantane’s effects extended beyond conventional stimulation, potentially involving membrane protection and improved cellular stress tolerance. Source: Eksp Klin Farmakol, 1998; Vestn Ross Akad Med Nauk, 1999. BEYOND PHYSICAL PERFORMANCE A 2014 study by Tallerova and colleagues examined Bromantane in C57BL/6 mice exposed to 30 days of chronic social stress. The stressed animals demonstrated reduced thymus weight, altered T-cell populations, and changes in CD4/CD8 ratios. Bromantane treatment reportedly restored several of these immune parameters toward control values. An interesting observation suggesting potential immunomodulatory effects under experimental stress conditions, although these findings do not establish clinical benefits in humans. WHERE DOES BEMETHYL FIT IN? Bemethyl is another Soviet-era actoprotector investigated for its potential effects on physical endurance and adaptation to physiological stress. A 2013 mouse study evaluated Bromantane and Bemethyl as reference actoprotective compounds under heat, cold, and hypoxic conditions. The pairing is interesting because both compounds emerged from research focused on maintaining performance under adverse conditions, rather than simply increasing central nervous system stimulation. Importantly, this doesn’t establish that combining them produces synergistic effects. THE LIMITATIONS Much of the foundational evidence comes from older Russian-language publications, with limited independent replication. The experiments discussed here are preclinical, and their results cannot be assumed to translate into comparable human outcomes. That distinction matters, especially as Bromantane continues gaining attention outside traditional research circles. For research and laboratory use only. Not for human consumption. Not medical advice. #Bromantane #Bemethyl #Actoprotectors #NootropicResearch #Pharmacology #ResearchChemicals #Elevate

I can’t grow my page but this kid has 257k followers reviewing toilets on Instagram. instagram.com/thetoiletkidda… You’re welcome by the way.

Exactly. Symptoms over numbers. You are not a reference range. You do not want to be a reference range, you want to be optimized.

GW-0742 and the Clean-Tool Question elevatedresearch.substack.co…

Can AI Predict Cancer Survival From a Single Photograph? Apparently, Yes. But There’s More to the Story. A new study in The Lancet Digital Health from Mass General Brigham investigated whether artificial intelligence could estimate mortality risk in cancer patients using nothing more than a facial photograph. The results are fascinating. Researchers developed FAHR-Face, an AI model initially trained on more than 40 million facial images, then adapted to estimate biological age and predict survival outcomes. The survival model was trained using approximately 34,000 photographs of cancer patients. Here’s what they found: • Patients classified in the highest-risk quartile had more than 3 times the mortality risk of those in the lowest quartile, even after adjusting for conventional clinical factors. • Results were validated in an independent Dutch cohort of nearly 5,000 patients. • In the US testing cohort, more than half of the highest-risk patients died within three months. That’s impressive predictive performance from a single photograph. But here’s where context matters. These weren’t random healthy individuals. They were cancer patients undergoing radiotherapy, many with advanced disease. Experienced clinicians can often recognize visible signs of severe illness, including muscle wasting, facial changes, and declining physical condition. Interestingly, the study didn’t directly compare AI predictions against physicians’ clinical judgment. There’s also the biological aging question. Changing facial expressions or lighting conditions shifted estimated facial age by approximately two years on average. And importantly, facial biological age isn’t necessarily cellular biological age. My takeaway: This is an impressive demonstration of AI identifying visual patterns associated with mortality risk. But predicting outcomes in seriously ill patients isn’t the same as predicting lifespan in healthy individuals. Nor does estimating facial age establish a reliable biomarker of systemic aging. Promising research? Absolutely. A validated clinical tool or something you should use to track longevity through selfies? Not yet. The distinction between predictive accuracy and clinical usefulness matters. #ArtificialIntelligence #CancerResearch #Longevity #BiologicalAge #MedicalResearch #Biohacking

Kisspeptin-10: The Upstream Signal Behind Testosterone Production Before enclomiphene, before hCG, and before most reproductive hormone therapies, there’s kisspeptin. It’s one of the key upstream regulators of the hypothalamic-pituitary-gonadal (HPG) axis, and the research behind it is fascinating. Interestingly, kisspeptin wasn’t originally discovered through hormone research. The KiSS-1 gene was first investigated for its role in suppressing cancer metastasis. In 2001, researchers identified kisspeptin as the natural ligand for GPR54 (KISS1R). By 2003, genetic studies demonstrated that individuals with defective GPR54 signaling could fail to undergo normal puberty. That discovery established kisspeptin as a critical regulator of reproductive function. The mechanism is straightforward: Kisspeptin → GnRH → LH/FSH → Testosterone Production & Spermatogenesis. Unlike hCG, which mimics LH activity directly at the testes, or enclomiphene, which reduces estrogen-mediated negative feedback, kisspeptin stimulates GnRH neurons further upstream. What does the human research show? • In healthy men, acute Kisspeptin-10 administration increased LH approximately threefold within 30 minutes. • A 2011 study demonstrated testosterone increasing from 16.6 to 24.0 nmol/L during a 22.5-hour infusion, approximately a 45% increase. • Research in women demonstrated that LH responsiveness varies across the menstrual cycle. • A 2015 comparison found kisspeptin produced approximately one-third of the LH response elicited by GnRH. These findings demonstrate genuine biological activity, but there’s an important limitation. More stimulation doesn’t necessarily mean better results. Continuous kisspeptin exposure in animal studies initially increased LH before producing desensitization and suppression. The HPG axis relies heavily on pulsatile signaling and feedback regulation. Simply stimulating the pathway continuously doesn’t guarantee sustained testosterone production. And the human evidence remains extremely limited. Most early studies involved only a handful of participants, with outcomes measured over hours rather than months. My takeaway: Kisspeptin-10 is an incredibly interesting research compound because it operates near the top of the reproductive hormone signaling cascade. But increasing LH temporarily isn’t the same as restoring fertility, and increasing testosterone acutely doesn’t establish long-term therapeutic benefits. The mechanism is compelling. The clinical evidence still has considerable catching up to do. Kisspeptin-10 remains investigational and is not FDA-approved. Educational purposes only. Not medical advice. #Kisspeptin10 #Endocrinology #Testosterone #Fertility #Biohacking #ElevateBiohacking

ALT-711 (Alagebrium): The experimental anti-aging drug designed to reverse arterial stiffness. A compound that appeared to reverse aspects of cardiovascular aging in animals, showed promise in early human trials, and ultimately failed to deliver consistent results in larger studies. Let’s break down the pharmacology. As we age, glucose and other reactive carbonyl compounds interact with long-lived proteins like collagen and elastin through a process known as glycation. Over time, this contributes to the formation of advanced glycation end products (AGEs). Some AGEs create crosslinks between structural proteins, reducing tissue elasticity. This is particularly relevant in the cardiovascular system. Arteries become less compliant, ventricular relaxation becomes impaired, and the heart must work harder against increasingly rigid blood vessels. Unlike compounds designed to prevent AGE formation, ALT-711 was developed with a more ambitious objective: Disrupt existing AGE-associated crosslinks and potentially restore tissue elasticity. Rather than simply slowing one proposed mechanism of cardiovascular aging, researchers wanted to reverse some of its accumulated structural consequences. And initially, the results looked promising. The preclinical research: • Diabetic rats demonstrated improvements in large-artery stiffness within weeks. • Older dogs experienced approximately 40% reductions in myocardial stiffness after one month of treatment. • Aged monkeys showed reductions in aortic stiffness lasting approximately six weeks before gradually returning toward baseline. These findings suggested that at least some components of age-related cardiovascular stiffness might be pharmacologically modifiable. Then came the human trials. After eight weeks: • Arterial compliance improved approximately 15% relative to placebo. • Pulse pressure decreased modestly. • The findings suggested potential improvements in vascular elasticity. For a compound targeting structural changes associated with aging, this was a meaningful early signal. Unfortunately, larger and longer studies told a different story. Two additional year-long studies in otherwise healthy older adults also failed to produce meaningful improvements in physical fitness or arterial stiffness. One study identified a modest signal involving cardiac stiffness, but the broader clinical outcomes were disappointing. And there’s another problem: We still don’t know whether ALT-711 actually worked through its proposed mechanism. A 2012 review raised serious questions about the ability of AGE crosslink breakers to disrupt established protein crosslinks inside living tissues. Researchers also identified substantial metal-chelating activity among compounds in this class. That introduces an alternative explanation for some of the observed biological effects. In other words, improvements in vascular function didn’t necessarily establish that existing AGE crosslinks were being broken. That’s an important distinction. So what happened to ALT-711? The compound never received FDA approval, and convincing evidence of meaningful clinical benefit never materialized. But I wouldn’t necessarily interpret its history as proof that targeting AGE-associated tissue stiffness is a dead end. It may simply mean that ALT-711 wasn’t the right molecule, its proposed mechanism was incomplete, or the clinical effects weren’t sufficiently robust. But improving arterial compliance in an eight-week study is very different from demonstrating sustained cardiovascular benefits, improved functional capacity, or reduced mortality. And none of these studies established that ALT-711 reverses biological aging. The underlying hypothesis is still interesting. The clinical evidence for this particular molecule just never caught up. #ALT711 #Alagebrium #Longevity #AdvancedGlycation #AGEs #CardiovascularHealth #Pharmacology #AntiAging #ElevateBiohacking

A drug that failed in schizophrenia just hit every endpoint in a Phase 3 trial for an entirely different disease. This is one of the more interesting examples of drug repurposing I’ve seen recently. Meet Bitopertin, a glycine transporter 1 (GlyT1) inhibitor originally developed by Roche. The original idea was to modulate glycine signaling in the brain to improve schizophrenia symptoms. Unfortunately, the clinical results were disappointing. Across three Phase 3 trials, only one of six treatment arms significantly outperformed placebo. Two additional studies targeting negative symptoms also failed. For most compounds, that’s where development ends. But Bitopertin had another potential application entirely unrelated to schizophrenia. Red blood cell precursors require glycine to synthesize heme. By inhibiting GlyT1, Bitopertin can reduce glycine availability and subsequently decrease production of certain heme precursors. That mechanism became particularly interesting for erythropoietic protoporphyria (EPP), a rare genetic disorder characterized by the accumulation of protoporphyrin IX (PPIX). PPIX is photoreactive. When exposed to sunlight, patients can experience severe, debilitating pain. Fast-forward to October 2026. Disc Medicine has now reported positive topline results from its Phase 3 APOLLO trial. The study enrolled 183 patients aged 12 and older, comparing Bitopertin against placebo over six months. The reported results: • 41.4% greater reduction in PPIX versus placebo. • Approximately 12 additional hours per month of pain-free light exposure compared with placebo. • 71% reduction in phototoxic reactions. • All reported primary and key secondary endpoints were met. Dizziness was the most frequently reported adverse event, occurring in approximately half of Bitopertin-treated participants. Most cases were described as mild and transient. Here’s where the regulatory story gets interesting. Earlier this year, the FDA declined approval because lowering PPIX alone wasn’t sufficient evidence of meaningful clinical benefit. Regulators wanted proof that the biochemical improvements translated into patients actually tolerating sunlight better. APOLLO was designed to address that exact concern. Disc Medicine now plans to resubmit its application before the end of 2026. One important caveat: These are company-reported topline findings, not yet independently evaluated in a peer-reviewed publication. Regulatory approval is also not guaranteed. My takeaway? A failed clinical trial doesn’t necessarily mean a failed molecule. Sometimes the pharmacology is legitimate, but the original therapeutic target simply isn’t where the compound delivers its greatest benefit. Bitopertin went from an unsuccessful CNS drug candidate to a potentially meaningful treatment for a rare metabolic disorder. That’s why drug repurposing deserves considerably more attention. The molecule didn’t change. Our understanding of where it might work did. #Bitopertin #GlyT1 #DrugRepurposing #ClinicalTrials #Phase3 #Biotechnology #Pharmacology #RareDisease #ElevateBiohacking For educational purposes only. Not medical advice.

ELEVATE Research is back online. elevateresearch.blog Deep, literature-backed write-ups on the mechanisms, molecular details, and published data behind peptides and nootropics. Structures, pathways, study findings, and regulatory context — nothing else. No marketing, no protocols. Just the research.

🧬 Today’s Kimera Research Spotlight: Seltorexant + Agomelatine Seltorexant is entering an interesting new chapter in clinical research, and it’s one worth paying attention to. Janssen’s latest Phase 3 trial, NCT07573176, is investigating Seltorexant as a standalone treatment for major depressive disorder (MDD), rather than simply using it as an adjunct to existing antidepressants. That’s an important distinction. The study aims to enroll approximately 600 adults, including elderly participants, with the primary endpoint measuring changes in MADRS depression scores over 42 days against placebo. An open-label extension will follow for up to six months. Previous Phase 3 research primarily examined Seltorexant alongside SSRIs and SNRIs. One pivotal study demonstrated superiority over placebo, while another comparing Seltorexant against quetiapine XR failed to meet its primary endpoint. So why is Seltorexant interesting? It comes down to its pharmacology. Seltorexant is a selective orexin-2 receptor (OX2R) antagonist. Unlike broader dual orexin receptor antagonists, it preferentially targets OX2R. Bonaventure et al. (2015) demonstrated approximately 100-fold selectivity for OX2R over OX1R, alongside reduced NREM sleep latency in animal models. More recently, Mesens et al. (2025) reported an early antidepressant signal in Phase 1b monotherapy research, including improvements that persisted after sleep-related items were excluded from depression scoring. That raises an interesting question: Could selective OX2R antagonism influence depressive symptoms beyond simply improving sleep? The clinical picture remains incomplete, but the research is progressing. Today’s featured Kimera compounds: 🔬 Seltorexant Selective OX2R antagonist Batch KC-SLX-01: 3 third-party reports Batch KC-SLX-02: 2 third-party reports 🔬 Agomelatine MT1/MT2 melatonin receptor agonist 5-HT2C receptor antagonist Interesting circadian and antidepressant pharmacology Batch KC-AGT-02: 2 third-party reports Both offer distinct mechanisms for researchers investigating sleep, circadian signaling, and mood-related pathways. Research documentation and batch-specific COAs can be reviewed at kimerachems.co/coas. 🧪 Shop Kimera Chems: kimerachems.co Use code ELEVATE for 10% off eligible research compounds. Seltorexant remains investigational and is not FDA-approved. Clinical trial activity does not establish efficacy or safety. #ad | Affiliate disclosure: I may earn a commission from qualifying purchases using my code. For research and laboratory use only. Not for human consumption. #KimeraChems #Seltorexant #Agomelatine #OX2R #Orexin #Neuroscience #Pharmacology #ResearchChemicals #ElevateBiohacking

Not all hero’s wear capes.

From a tactical medicine background, it’s interesting to track the preclinical research on certain peptides and nootropics that scientists are studying for their activity in models related to tissue repair signaling, recovery processes, and cognitive performance under stress or high-demand conditions. A lot of that work centers on growth factor pathways. Researchers look at how specific compounds interact with signaling involved in cell proliferation, angiogenesis, and extracellular matrix remodeling in controlled rodent or in-vitro models. The goal is usually to map how those pathways respond under experimental injury or inflammatory conditions, and whether the compound produces measurable changes in tissue-level markers without broad off-target effects. On the recovery side, some studies examine mitochondrial function and cellular energy handling. In preclinical models that impose metabolic or oxidative stress, scientists measure things like ATP production, mitochondrial biogenesis markers, and resilience to oxidative damage. The interest is in understanding whether targeted modulation of those systems can support more efficient cellular recovery processes under lab conditions that mimic high physiological demand. Cognitive research tends to focus on neurotransmitter systems under stress models. Work on compounds that interact with dopaminergic, glutamatergic, or cholinergic pathways often looks at performance on attention, working-memory, or decision-making tasks after sleep disruption, restraint stress, or other experimental challenges. The emphasis is on selectivity, how cleanly a compound influences the intended pathway versus producing widespread changes in brain signaling. Across these areas the consistent theme is mechanistic..researchers are always trying to understand how specific molecular targets behave in controlled settings that approximate the kinds of physical and cognitive loads seen in demanding operational environments. #ResearchUseOnly #Peptides #Nootropics #TacticalMedicine #EvidenceBased #KimeraChems

Interesting